Inactivated Vaccines Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts

The Inactivated Vaccines Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Inactivated Vaccines Market Size During the Forecast Period?
The market size for inactivated vaccines has been on a progressively increasing trend in the past few years. The industry is projected to escalate from a value of $6.19 billion in 2024 to $6.44 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.0%. Factors such as the drive towards polio eradication, implementation of flu vaccination schemes, the emergence of novel infectious diseases, and regulatory green lights have been instrumental in the growth observed during the historic timeline.

In the coming years, the market size for inactivated vaccines is projected to experience consistent growth. It is expected to reach a value of $7.75 billion by 2029, with a compound annual growth rate (CAGR) of 4.7%. Various factors that can attrie to the predicted growth during the forecast period include readiness for pandemics, increased vaccine coverage, advancements in biomanufacturing, and initiatives towards health equity. The major trends during the forecast period will likely be mrna vaccine platforms, combination vaccines, thermostable vaccines, and digital vaccine passports.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13018

What Are the High-Growth Segments in the Inactivated Vaccines Market?
The inactivated vaccines market covered in this report is segmented -

1) By Type: Viral Vaccine, Bacterial Vaccine
2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation
3) By Distriion Channel: Hospital Pharmacy, Retail Pharmacy, Other Distriion Channels

Subsegments:
1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine
2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

What Key Drivers Are Expected to Influence Future Inactivated Vaccines Market Growth?
The rise in infectious diseases is predicted to spur the expansion of the inactivated vaccine market. These diseases, brought about by harmful organisms such as bacteria, viruses, fungi, or parasites, can be transmitted among individuals and can lead to various symptoms and health problems. An example of such a disease is Tuberculosis. Inactivated vaccines, which utilize non-living pathogens to stir an immune reaction, are effective in preventing diseases like polio, hepatitis A, and influenza. For example, in November 2023, an article by the Centers for Disease Control and Prevention, a national public health agency in the US, revealed that the number of tuberculosis cases in the US had grown from 8,320 in 2022 to 9,615 in 2023, indicating an increase of 1,295 cases. Therefore, the escalating occurrence of infectious diseases is fueling the growth of the inactivated vaccine market. The inactivated vaccines market is also expected to benefit from the growth in immunization initiatives. These initiatives, which are systematic actions or campaigns to vaccinate individuals or communities against specific infectious diseases, play a crucial role in the inactivation vaccines market. Intensified vaccination campaigns result in increased demand for inactivated vaccines, stimulating the market's growth and encouraging investment in research and development. For instance, according to the World Health Organization, a Switzerland-based intergovernmental organization, vaccines avert the death of 4-5 million individuals worldwide every year by offering protection against infectious diseases like hepatitis, diphtheria, tetanus, pertussis, measles, and polio. Furthermore, in 2022, approximately 84% of global infants were administered three doses of the polio vaccine. Similarly, it was projected that 84% of infants in nations using oral polio vaccine received their initial dose of inactivated polio vaccine in the same year. Therefore, the escalating immunization initiatives are propelling the growth of the inactivated vaccines market.

Which Companies Hold the Largest Share Across Different Inactivated Vaccines Market Segments?
Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

What Are the Latest Developing Trends in the Inactivated Vaccines Market?
In an effort to maintain their market standing, top-tier entities in the inactivated vaccines sector are pioneering novel and enhanced inactivated vaccines. An inactivated vaccine is comprised of inactivated viruses, bacteria, or alternative pathogens that were previously grown in culture and subsequently exterminated to nullify their ability to cause diseases. For example, GSK PLC, a pharmaceutical and biotechnology company based in the UK, launched a fresh inactivated vaccine named Shingrix in January 2022 to assist with defending against shingles (Herpes zoster). Shingrix is an adjuvanted, non-live, recombinant subunit vaccine delivered intramuscularly in a couple of doses. Initially, the vaccine was recommended for people aged 50 or above. It has recently been extended to include individuals 18 and up who are at an increased danger of contracting shingles due to immunosuppression or immunodeficiency resulting from a recognized disease or therapy.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

What Are the Emerging Geographies for The Inactivated Vaccines Market Growth?
North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Inactivated Vaccines Market?
2. What is the CAGR expected in the Inactivated Vaccines Market?
3. What Are the Key Innovations Transforming the Inactivated Vaccines Industry?
4. Which Region Is Leading the Inactivated Vaccines Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.